Generic Medicine Info
Should be taken with food.
Pre-existing severe bone marrow depression, severe neurologic toxicity. Lactation. Concomitant use w/ antidepressants of the MAOI class.
Special Precautions
Patient previously treated w/ other myelosuppressive agents. Pregnancy. Patient Counselling This drug is an irritant, avoid contact w/ skin or mucous membranes. Monitoring Parameters Perform peripheral blood counts at least mthly, prior to initiation of each course of therapy and as clinically indicated. Monitor neurologic function regularly. Monitor for GI upset and anaemia.
Adverse Reactions
Bone marrow depression, manifested by leucopenia, thrombocytopenia, anaemia; nausea, vomiting, peripheral (e.g. neuropathy) and central (e.g. ataxia, depression, confusion, drowsiness, hallucination, mood disorder, dizziness, vertigo) neurotoxicity. Rarely, rashes, pruritus, alopecia, hepatotoxicity.
Drug Interactions
Reduced activity w/ pyridoxine. Increased half-life and toxicity w/ inhibitors of microsomal metabolism (e.g. cimetidine).
ATC Classification
L01XX03 - altretamine ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on altretamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in